Drug intelligence / Profile preview

Goldmune

Development stage: Unknown
Lead developer: Vaxcell-Bio Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

Goldmune is an immunotherapy product developed by Vaxcell-Bio Therapeutics for the treatment of cancer and immune conditions in companion animals. It is designed to enhance the host's immune function to combat malignancies and manage immune-mediated disorders. While specific molecular targets and the exact mechanism of action are not publicly disclosed, the product is part of Vaxcell-Bio's veterinary portfolio and has received regulatory approval for use in pets in South Korea. It is often mentioned alongside Vaxleukin-15 (boxleukin-15), another of the company's veterinary immunotherapy candidates.

Brand names: Goldmune골드뮨
Other names: 골드뮨

Beyond the preview

Go deeper on Goldmune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Goldmune.

Explore the full profile